InMed receives Nasdaq delisting notice for equity shortfall; merger to cure

InMed Pharmaceuticals Inc.

• Nasdaq notice on 9/16/2026: shareholders' equity $1,075,007 vs $2.5M required under Rule 5550(b)(1).
• 45 days to submit compliance plan (by Nov 2, 2026); up to 180-day extension possible until Mar 15, 2027.
• Deficiency driven by Merger expenses with Mentari; combined company expects ~$490M gross proceeds, closing Q4 2026.
• Stock up ~99.8% since Merger announcement; shares continue trading on Nasdaq under INM.